Items Tagged ‘PD-1’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


June 8th, 2016

Tecentriq® Approved for Bladder Cancer

By

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is […]

View full entry

Tags: atezolizumab, Bladder Cancer, inhibitor, News, PD-1, PD-L1, Stage IV/Metastatic Bladder Cancer, Tecentriq, urothelial carcinoma


December 23rd, 2014

FDA Approves Nivolumab for Advanced Melanoma

By

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab (Yervoy) and, for melanoma patients whose tumors express the BRAF V600 mutation, for use after treatment with ipilimumab […]

View full entry

Tags: fda, Melanoma, News, nivolumab, opdivo, PD-1, Recurrent Melanoma, Stage IV Melanoma


December 18th, 2014

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of Medicine, PD-1 blockade has demonstrated effectiveness in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is a […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, HL, Hodgkin's Lymphoma, Lymphoma, News, nivolumab, PD-1, Progressive Relapsed Hodgkin's Lymphoma


December 10th, 2014

Initial Results of PD-1 Checkpoint Inhibitors Evaluated in Triple-Negative Breast Cancer Presented in San Antonio

By

The initial results from a phase 1 trial evaluating the checkpoint inhibitor Keytruda® (pembrolizumab) in patients with heavily pretreated triple-negative breast cancer were recently reported at the San Antonio Breast Cancer Symposium (SABCS). The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune […]

View full entry

Tags: Breast Cancer, immunotherapy, keytruda, Metastatic Breast Cancer, News, PD-1, Recurrent Breast Cancer, tnbc, Triple Negative Breast Cancer


November 20th, 2014

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma

By

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently published online in the New England Journal of Medicine.[1] Of the more than one million new diagnoses of skin cancer each year, […]

View full entry

Tags: immunotherapy, Melanoma, melaoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma


October 13th, 2014

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma

By

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve […]

View full entry

Tags: Melanoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma


August 4th, 2014

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer

By

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated stage IV non–small cell lung cancer (NSCLC). These results were recently presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO 2014) in […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, PD-1, pembrolizumab, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


July 31st, 2014

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity

By

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO 2014) in Chicago in June. Of the more than one million new diagnoses of skin cancer […]

View full entry

Tags: Melanoma, News, PD-1, pembrolizumab, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma


July 30th, 2014

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma

By

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research showing promise for pembrolizumab in advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000 involve […]

View full entry

Tags: Melanoma, News, PD-1, pembrolizumab, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma


July 8th, 2014

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results

By

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that the drug was likely to prolong survival. Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to […]

View full entry

Tags: Melanoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma